Levetiracetam Tablet
Product Images NDC 68788-8843

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-8843). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of Levetiracetam, a compound showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

A bar graph comparing the percentage of patients across three groups: Placebo (95 patients) with approximately 7.4%, Levetiracetam 1000 mg/day (97 patients) with about 37.1%, and Levetiracetam 3000 mg/day with roughly 39.6%. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar graph showing the percentage of patients on placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. Percentages increase progressively from about 6.3% with placebo to 20.8% with 1000 mg/day, and 35.2% with 2000 mg/day of levetiracetam.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

A bar chart comparing the percentage of patients for placebo and Levetiracetam 3000 mg/day groups. The placebo group (N=104) shows about 14.4% of patients, while the Levetiracetam group (N=180) shows about 39.4%. The vertical axis is labeled as percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group includes 97 patients with about 19.6%, and the Levetiracetam group includes 101 patients with about 44.6%. An asterisk highlights the Levetiracetam bar.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The chart shows approximately 19.6% for the Placebo group and 43.1% for the Levetiracetam group, with the Levetiracetam bar marked with an asterisk indicating statistical significance.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

Bar chart comparing the percentage of patients between two groups: Placebo (N=84) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis represents the percentage of patients from 0% to 100%, with Levetiracetam showing a higher patient percentage than Placebo.*

FDA Label Image

Levetiracetam Tab Usp 500mg (Levetiracetam Tablets 9)

Levetiracetam Tab USP 500 mg tablet packaging label by Preferred Pharmaceuticals, Inc., manufactured by Zhejiang Jingxin Pharmaceutical Co., Ltd. The label indicates the tablet is film-coated, oval, green, scored, and imprinted with JX012. Storage instructions specify keeping at 20°-25°C (68°-77°F). The label includes caution about federal law prohibiting transfer to others and features bilingual instructions for tablet dosage in English and Spanish.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.